Shenzhen Chipscreen Biosciences Co
Shenzhen Chipscreen Biosciences Co., Ltd. engages in the research and development of original small molecule drugs. The company develops Chidamide, a subtype-selective histone deacetylase inhibitor for the treatment of peripheral T-cell lymphoma and advanced hormone receptor-positive breast cancer; Chiglitazar Sodium, a PPAR pan-agonist for the treatment of metabolic diseases; and Chiauranib, a t… Read more
Shenzhen Chipscreen Biosciences Co (688321) - Total Assets
Latest total assets as of September 2025: CN¥3.63 Billion CNY
Based on the latest financial reports, Shenzhen Chipscreen Biosciences Co (688321) holds total assets worth CN¥3.63 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Shenzhen Chipscreen Biosciences Co - Total Assets Trend (2016–2024)
This chart illustrates how Shenzhen Chipscreen Biosciences Co’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Shenzhen Chipscreen Biosciences Co - Asset Composition Analysis
Current Asset Composition (December 2024)
Shenzhen Chipscreen Biosciences Co's total assets of CN¥3.63 Billion consist of 33.3% current assets and 66.7% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 11.5% |
| Accounts Receivable | CN¥178.39 Million | 5.5% |
| Inventory | CN¥40.84 Million | 1.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥600.50 Million | 18.5% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Shenzhen Chipscreen Biosciences Co's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shenzhen Chipscreen Biosciences Co's current assets represent 33.3% of total assets in 2024, a decrease from 56.1% in 2016.
- Cash Position: Cash and equivalents constituted 11.5% of total assets in 2024, down from 26.9% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 18.0% of total assets, a decrease from 20.0% in 2016.
- Asset Diversification: The largest asset category is intangible assets at 18.5% of total assets.
Shenzhen Chipscreen Biosciences Co Competitors by Total Assets
Key competitors of Shenzhen Chipscreen Biosciences Co based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Shenzhen Chipscreen Biosciences Co - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Shenzhen Chipscreen Biosciences Co generates 0.20x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Shenzhen Chipscreen Biosciences Co is currently not profitable relative to its asset base.
Shenzhen Chipscreen Biosciences Co - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.87 | 2.89 | 5.24 |
| Quick Ratio | 1.79 | 2.76 | 5.15 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥622.49 Million | CN¥ 718.25 Million | CN¥ 622.17 Million |
Shenzhen Chipscreen Biosciences Co - Advanced Valuation Insights
This section examines the relationship between Shenzhen Chipscreen Biosciences Co's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.84 |
| Latest Market Cap to Assets Ratio | 0.35 |
| Asset Growth Rate (YoY) | 1.5% |
| Total Assets | CN¥3.25 Billion |
| Market Capitalization | $1.13 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Shenzhen Chipscreen Biosciences Co's assets below their book value (0.35 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Shenzhen Chipscreen Biosciences Co's assets grew by 1.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Shenzhen Chipscreen Biosciences Co (2016–2024)
The table below shows the annual total assets of Shenzhen Chipscreen Biosciences Co from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.25 Billion | +1.49% |
| 2023-12-31 | CN¥3.20 Billion | +10.62% |
| 2022-12-31 | CN¥2.90 Billion | +52.86% |
| 2021-12-31 | CN¥1.89 Billion | +9.74% |
| 2020-12-31 | CN¥1.73 Billion | +2.06% |
| 2019-12-31 | CN¥1.69 Billion | +136.12% |
| 2018-12-31 | CN¥716.34 Million | +9.19% |
| 2017-12-31 | CN¥656.02 Million | +62.73% |
| 2016-12-31 | CN¥403.13 Million | -- |